Kyoko Otsuka

Learn More
Optimal chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD) is established for paclitaxel and carboplatin, but is otherwise controversial.(More)
Crizotinib-an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-is effective in non-small-cell lung cancers (NSCLCs) that express ALK. Here, we report a patient with ALK-positive lung(More)